GlaxoSmithKline
NEWS
GlaxoSmithKline announced it will acquire the Tesaro, based in Waltham, Mass., for $5.1 billion. For GSK, the deal marks an increased focus on oncology as it focuses on high growth areas.
Noting that from 1998 to 2017 there have been about 146 failed shots at developing drugs for Alzheimer’s disease, PhRMA released a report on the state of the industry. This would not lead most people to think there are many reasons to be optimistic about Alzheimer’s disease research, but the report does believe there are good reasons to be.
A Small Group of Pharma Companies Is Making the Bulk of Medicines Necessary for Developing Countries
There are 7 billion people in the world. Of those, 5 billion have access to life-saving medications, while 2 billion do not. That is a gap that pharmaceutical companies can help close through increased R&D programs, logistical initiatives and the lowering of prices, the Access to Medicine Foundation announced Tuesday.
When consumers have their genome tested by services like 23andMe and Ancestry.com, the companies hold the rights to the genetic information, which they often sell to biopharmaceutical companies. Nebula Genomics is taking a different approach.
Kymera Therapeutics secured $65 million in a Series B funding round that was supported, in part, by the investment arms of Pfizer and Sanofi.
Vivek Ramaswamy’s Roivant Sciences, the umbrella company to 14 Vant companies, including Datavant, Enzyvant Sciences, Urovant Sciences and others, raised another $200 million in equity financing.
Indianapolis-based Eli Lilly announced that its diabetes drug Trulicity (dulaglutide) reduced major adverse cardiovascular events (MACE) in its REWIND clinical trial.
Biopharma companies make key appointments to fill leadership positions. Let’s take a look!
In an interview with S&P Global Market Intelligence, Alex Hoos, head of oncology at GSK, said the company could narrow its drug development focus to aim at products that will generate growth.
JOBS
IN THE PRESS